Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

Mabion submits MAA for rituximab biosimilar Mabion-CD20

June 5, 2018

Cyxone chooses to complete acquisition of rabeximod

June 5, 2018

EMA CHMP recommends approval of Sandoz adalimumab biosimilar

June 4, 2018

FDA approves Olumiant 2 mg for moderate to severe rheumatoid arthritis

June 4, 2018

Astellas submits application for marketing approval of peficitinib in Japan

June 1, 2018

Phase II EQUATOR study of filgotinib in psoriatic arthritis meets primary endpoint

May 31, 2018

ImmuPharma releases further data analysis from pivotal trial of Lupuzor in SLE

May 29, 2018

Croma-Pharma identifies H2S-releasing compounds

May 28, 2018

Lupin submits MAA to the EMA for etanercept biosimilar

May 28, 2018

First patient enrolled in SARA-INT study of Sarconeos in sarcopenia

May 28, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...